Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Royalty Pharma Plc Cl A (NQ: RPRX )

26.66 +0.06 (+0.23%)
Streaming Delayed Price Updated: 1:00 PM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,411,354
Open 26.60
Bid (Size) 26.63 (7)
Ask (Size) 26.65 (44)
Prev. Close 26.60
Today's Range 26.46 - 26.66
52wk Range 25.10 - 31.66
Shares Outstanding 388,132,400
Dividend Yield 3.15%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Royalty Pharma to Present at Upcoming Investor Conferences
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma Announces Inaugural Prize for Impact in Healthcare
From Royalty Pharma plc
Via GlobeNewswire

Performance

YTD
-5.70%
-5.70%
1 Month
-1.80%
-1.80%
3 Month
-8.48%
-8.48%
6 Month
+1.02%
+1.02%
1 Year
-0.89%
-0.89%

More News

Read More
3 High-Yield Dividend Stocks You Can Buy With $130 Now and Hold at Least a Decade
Via The Motley Fool
Royalty Pharma to Acquire Royalty Interest in Geron’s RYTELO for $125 Million
From Royalty Pharma plc
Via GlobeNewswire
Insights Ahead: Royalty Pharma's Quarterly Earnings
Via Benzinga
Peering Into Royalty Pharma's Recent Short Interest
Via Benzinga
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields
Via Benzinga
Royalty Pharma Reports Third Quarter 2024 Results
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma and Syndax Pharmaceuticals Enter Into $350 Million Royalty Funding Agreement for Niktimvo
From Royalty Pharma plc
Via GlobeNewswire
3 Dividend Growth Stocks to Buy Now for a Lifetime of Passive Income
Via The Motley Fool
Royalty Pharma to Announce Third Quarter 2024 Financial Results on November 6, 2024
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma Declares Fourth Quarter 2024 Dividend
From Royalty Pharma plc
Via GlobeNewswire
2 No-Brainer Dividend Stocks to Buy With $100 in October
Via The Motley Fool
2 High-Yield Dividend Stocks Near 52-Week Lows: Are They Buys Now?
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
3 High-Yield Dividend Stocks Down by More Than 39% to Buy Now and Hold at Least a Decade
Via The Motley Fool
2 Unstoppable Dividend Growth Stocks You Can Buy Now With $100
Via The Motley Fool
Rare Disease-Focused Ascendis Pharma Stock Falls On Underwhelming Q2 Earnings, Guidance Cut
Via Benzinga
Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma to Present at Morgan Stanley’s 22nd Annual Global Healthcare Conference
From Royalty Pharma plc
Via GlobeNewswire
Jim Cramer: This Financial Stock Is A Buy, Core Scientific Is A 'Very Overvalued Situation'
Via Benzinga
RPRX Stock Earnings: Royalty Pharma Misses EPS, Misses Revenue for Q2 2024
Via InvestorPlace
Royalty Pharma Reports Second Quarter 2024 Results
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human Capital
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma to Announce Second Quarter 2024 Financial Results on August 8, 2024
From Royalty Pharma plc
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.